Introduction
Most of the patients find esophagogastroduodenoscopy (EGD) an uncomfortable procedure.
Midazolam a short acting benzodiazepine, due to its good ante grade amnesic effect is frequently used intravenously to induce conscious sedation in patients undergoing EGD 1 . The efficacy of its effect has been very well demonstrated. [2] [3] [4] [5] However IV administration of sedative drugs for outpatient EGD have been related to certain risks like respiratory depression, hypotension etc . 1, 6 . To manage them effectively require trained personnel, well equipped recovery facilities, close patient monitoring adding extra burden on health care professionals and it is not that ideal for office based procedure like EGD. In our setup, patients undergoing EGD are not given sedative agents due to large patient load. Since IV administrations of sedative agent have lot of risks, oral administration of sedation is an alternative for outpatient EGD [7] [8] [9] [10] [11] . Oral administration being safe, effective and devoid of many disadvantages, has been shown to be useful in premedication for other endoscopic procedure [12] [13] . Use of oral midazolam in Indian patients undergoing EGD has not been studied extensively. This randomized placebo controlled trial performed to assess the use of oral midazolam as premedication for adults undergoing effective EGD.
Patients and Methods
This prospective study was conducted in government medical college, endoscopy centre from September 2018 to November 2018. Patients between the ages of 18 years to 70 years who were scheduled for elective diagnostic EGD and considered by American society of anesthesia (ASA) criteria to be class 1 to 2 were considered eligible for inclusion. Exclusion criteria werehaving history of esophagectomy, gastrectomy, surgery on the upper gi tract, ASA class 3 to 4, alcoholism, pregnancy, patient on antipsychotic drugs and patient allergic to midazolam. All patients were advised not to drive and perform mechanical work for remaining day after ingestion of medication. The study was approved by the research ethics committee and consent was taken from every patient. Demographic data including age, sex, body weight, education level, baseline vital signs and anxiety score (10 cm visual analogue scale: 0, no anxiety to 10, extreme anxiety) were collected. Patients were randomly selected to take 7.5mg of midazolam in tablet form (midazolam group-MG) or a placebo (control group-CG) as premedication 20 min before EGD procedure. All the participants in the trial were blinded to the treatment modality. After ingestion of medicine every patient was monitored continuously for pulse and oxygen saturation and blood pleasure were recorded before the procedure and every five minutes after EGD until recovery. EGD was performed twenty minutes after ingestion of medicine. Topical pharyngeal anesthesia was given with lidocaine spray before procedure. EGD was performed by pentax EG-290Kp gastroscope. A preprocedure anxiety score was obtained by using 10 cm unscaled visual analogue scale. Additional requirement of oxygen and sedation during procedure were noted. After the procedure every patient remained in recovery room until fully recovered. Full recovery was defined as hemodynamic stability and orientation to time, place and person. After the patient fully recovered a questionnaire was used to asses anxiety during EGD (10cm unscaled VAS), overall tolerance of the procedure, the extent of amnesia and willingness to repeat the procedure. The primary outcome was the anxiety score during EGD. Secondary outcomes were overall tolerance, extent of amnesia, patient willingness to repeat the procedure and episode of hypotension (systolic blood pressure <90 mm hg) and desaturation (arterial oxygen saturation <90%)
Statistical methods
Statistical analysis was performed with a statistical software package-SPSS. Comparisons were carried out by the pearson chi-square test where appropriate for categorical data, the student t test for parametric data and mann-whitney u test for non parametric data. A two sided p value < 0.05 was considered significant. 3%) . All of these patients were treated effectively by administration of oxygen. All patients were able to leave the endoscopy room 30 minutes after procedure. One patient in MG complained of dizziness after discharge, only reassurance was required. No drug related side effects were observed.
Discussion
Many endoscopist perform EGD in unsedated patients, but a proportion of patient will benefit from sedative drug during the procedure [14] [15] . The ideal sedative agent for short procedure should be safe, effective, easy to administer, rapid onset and recovery. Oral midazolam fulfill these qualities and it is widely used in both children and adult as a premedication to surgery [16] [17] . Its use for endoscopy is not common in routine practice. Oral sedative agent for patient undergoing EGD has been shown to be useful [7] [8] [9] [10] . Hedenbro et al (7) used oral triazolam as premedication in adults undergoing EGD and found that it relieved patient discomfort during procedure. Oral lonazepam has been shown to improve patient discomfort during bronchoscopy 13 . In a study by kinganeswaran et Further studies are required regarding this issue.
In conclusion, the result of this prospective randomized control trial shows that oral administration of midazolam to patients undergoing UGI endoscopy is safe and effective. Oral midazolam can be recommended as an alternative to IV administration of sedative drugs in endoscopy units where IV administration of sedative is not routines because this will improve patient tolerance for UGI endoscopies.
